Insilico’s $2.5b AI drug discovery deal targets neuroimmune failure

Partnership with SK Biopharma signals growing confidence that AI can accelerate search for treatments for some of brain’s toughest diseases. For all the excitement surrounding AI, one question still hangs over the biotechnology sector: can AI actually help deliver better medicines? A new collaboration between generative AI-driven drug discovery company Insilico Medicine and Korean-based biotech […] The post Insilico’s $2.5b AI drug discovery deal targets neuroimmune failure appeared first on Longevity.Technology .

This story was reported by Longevity.Technology. EUROPES curates Europe's most relevant coverage — read the full report at the original source.